MNTC logo

Mentice AB (publ) Stock Price

OM:MNTC Community·SEK 416.3m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

MNTC Share Price Performance

SEK 14.80
-9.50 (-39.09%)
SEK 12.00
Fair Value
SEK 14.80
-9.50 (-39.09%)
23.3% overvalued intrinsic discount
SEK 12.00
Fair Value
Price SEK 14.80
AnalystLowTarget SEK 12.00

MNTC Community Narratives

AnalystLowTarget·
Fair Value SEK 12 23.3% overvalued intrinsic discount

Portable Simulation Shift And Rising R&D Needs Will Pressure Long-Term Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
SEK 12
23.3% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
8.38% p.a.
Profit Margin
0.022%
Future PE
64.03x
Price in 2028
SEK 0.13

Trending Discussion

Updated Narratives

MNTC logo

Portable Simulation Shift And Rising R&D Needs Will Pressure Long-Term Prospects

Fair Value: SEK 12 23.3% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with reasonable growth potential.

2 Risks
3 Rewards

Mentice AB (publ) Key Details

SEK 276.0m

Revenue

SEK 26.3m

Cost of Revenue

SEK 249.6m

Gross Profit

SEK 292.9m

Other Expenses

-SEK 43.3m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-1.54
90.46%
-15.69%
0%
View Full Analysis

About MNTC

Founded
1998
Employees
128
CEO
Frans Venker
WebsiteView website
www.mentice.com

Mentice AB (publ), together with its subsidiaries, develops, sells, and markets solutions for training and decision support in the clinical area of interventional angiography in cardiology, neurology, vascular surgery, and radiology. It operates through the Mentice VIST, Physical Sim, and Ankyras segments. The company offers virtual simulation products, including VR simulator platforms; procedural learning models; patient simulator accessories and extensions for endovascular therapies; and Angiosuite integrations, such as the VIST virtual patient and Laerdal SimMan vascular medical simulator. It also provides flow model products, which include physiological flow systems, silicone and 3D printed vessels, and flow system accessories; Ankyras, a clinical decision application; Mentice Live, a cloud-based learning center for medical technology industry and healthcare providers; Mentice Right Heart Cath app, a mobile solution for interactive real-time exploration into the right heart catheterization procedure; Vascular Twin, an anatomical replication for procedural and device adoption; research and development services; and professional support services for installation, training, and warranty services. It operates in Europe, the Middle East, Africa, the Asia Pacific, and the Americas. Mentice AB (publ) was founded in 1998 and is headquartered in Gothenburg, Sweden.

Recent MNTC News & Updates

Recent updates

No updates